Clene (NASDAQ: CLNN) Participates in Top Investor Conferences to Showcase Lead Drug Candidate CNM-Au8
Clene (NASDAQ: CLNN) and its subsidiary Clene Nanomedicine Inc. showcase latest achievements and updates on lead drug candidate CNM-Au8 at top investor conferences, offering new hope for patients with ALS and other neurodegenerative conditions.
This news matters as it highlights the participation of Clene and its subsidiary in important investor conferences to present breakthrough achievements and key updates on their lead drug candidate, offering hope for patients with ALS and other neurodegenerative conditions.
